Enhanced Recopvery After HIPEC for Peritoneal Carcinamatosis
Not Applicable
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2019/08/020496
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
. Patients with a peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
ii. Peritoneal carcinomatosis Index (PCI) Score any iii. Age >18 years and <65 years
iv. European Cooperative Oncology Group (ECOG) Performance status 0-1
vi. No functional disturbance in bone marrow; WBC at least 3,000/mm3, Platelet count of atleast125,000/mm3.
vii. No functional disturbance in liver; Bilirubin less than 2.5 mg/dL, PT-INR < 1.5
viii. No function disturbance in kidney; Creatinine no greater than 1.5 times upper limit of normal.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To assess the compliance of ERAS protocol in patients with peritoneal carcinomatosis undergoing CRS & HIPEC <br/ ><br>2. To identify the correlation of the compliance pattern with morbidity & mortality <br/ ><br>Timepoint: 30 Days
- Secondary Outcome Measures
Name Time Method To assess the length of ICU stay, hospital stay & factors associated with morbidity.Timepoint: 30 days